Jeil Pharm (002620) — Capital Reinvestment Ratio
Jeil Pharm (002620) has a Capital Reinvestment Ratio of 3.85x as of March 2026, meaning it reinvests 4% of its operating cash flow (₩447.08 Million) in capital expenditures (₩1.72 Billion). Check tangible equity quality of Jeil Pharm to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Jeil Pharm Capital Reinvestment Ratio (2011–2025)
This chart tracks Jeil Pharm's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see how efficiently does Jeil Pharm generate cash.
Annual Capital Reinvestment Ratio for Jeil Pharm (2011–2025)
Year-by-year Capital Reinvestment Ratio for Jeil Pharm from 2011 to 2025. See 002620 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 23.90x | ₩390.26 Million | ₩9.33 Billion | ▲ +1481.9% |
| 2024 | 1.51x | ₩4.54 Billion | ₩6.86 Billion | ▼ -14.5% |
| 2021 | 1.77x | ₩13.40 Billion | ₩23.69 Billion | ▲ +18.3% |
| 2019 | 1.49x | ₩25.22 Billion | ₩37.69 Billion | ▲ +201.2% |
| 2017 | 0.50x | ₩5.92 Billion | ₩2.94 Billion | ▼ -81.4% |
| 2016 | 2.67x | ₩11.36 Billion | ₩30.33 Billion | ▲ +8.7% |
| 2015 | 2.46x | ₩2.74 Billion | ₩6.74 Billion | ▲ +159.2% |
| 2011 | 0.95x | ₩23.63 Billion | ₩22.40 Billion | — |